We invite you to learn more about Iomab-B and Actimab-A.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies are ARC’s or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Our most advanced product candidate, Iomab-B, is an ARC comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory Acute Myeloid Leukemia age 55 and older. We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for newly diagnosed, older patients unfit for standard induction therapy. Our Actinium Warhead Enabling Technology Platform is focused on leveraging our know how and intellectual property to create additional ARC drug candidates by labeling Ac225 to various targeting moieties.
Brands: Iomab-B (Phase 3 drug candidate) for relapsed/refractory AML and BMT
Actimab-A (Phase 2 drug candidate) for newly diagnosed AML
Actimab-M (Phase 1 drug candidate) for refractory Multiple Myeloma